- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07944235
Preoperative and Postoperative Radiosurgery in Patients With Brain Metastases Undergoing Surgery (PREOPRAD)
Randomized Phase II/III Study Comparing Preoperative Radiosurgery Versus Postoperative Radiosurgery in Patients With Brain Metastases Eligible for Surgery: Correlation With Histopathological Factors and Radiomic Analysis.
The PREOP-RAD study aims to evaluate the feasibility, safety, and efficacy of preoperative surgical resection (SRS) in patients with large brain metastases requiring surgical resection, taking into account potential differences based on sex/gender, compared to postoperative SRS, within the Spanish healthcare context.
More specifically, the study seeks to:
- Assess the clinical and radiological outcomes of the preoperative strategy in terms of local control, progression-free survival, and the occurrence of radionecrosis or neuromuscular dysfunction (nMD) compared to the postoperative strategy.
- Study the histopathological profile of resected lesions before and after SRS, searching for personalized biomarkers of response and toxicity.
- Identify patterns based on radiomic analysis and advanced imaging related to therapeutic response, recurrence, and complications.
PREOP-RAD is a prospective, randomized, multicenter study that will include patients diagnosed with symptomatic, single or multiple brain metastases ≥2 cm who are candidates for surgical resection. The procedure will consist of preoperative administration of SRS (1-5 fractions, depending on location and size), followed by surgery within a maximum of 10 days.
The intervention will be carried out in coordination with the Neurosurgery and Radiation Oncology Departments of each participating center, using a standardized workflow. The collection of surgical samples will allow for centralized histopathological studies. Furthermore, pre- and postoperative images will undergo radiomic analysis using artificial intelligence tools to explore similarities and correlate morphological and textural characteristics with clinical outcomes.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
Preoperative SRS has emerged as a promising alternative. Administered before surgery, it allows for more precise planning, less exposure of healthy tissue, avoids delays due to surgical complications, and reduces the risk of neuromuscular dysfunction (nMD) by eliminating prior tumor manipulation. Recent retrospective studies and meta-analyses show local control rates similar to postoperative SRS, with a lower incidence of radionecrosis (1.5% vs. 14.6%) and nMD (3% vs. 17%). However, most of this data comes from North American centers, and prospective studies evaluating this strategy within the Spanish healthcare system, and especially its differentiated impact on patients by sex, are lacking.
Typ studiów
Zapisy (Szacowany)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Badajoz
-
Badajoz, Badajoz, Hiszpania, 06080
- Jeszcze nie rekrutacja
- Hospital Universitario de Badajoz
-
Kontakt:
- Victoria Vera Barragán, MD
- Numer telefonu: +34924 21 81 00
- E-mail: victoria.vera@salud-juntaex.es
-
-
Galicia
-
Vigo, Galicia, Hiszpania, 36214
- Jeszcze nie rekrutacja
- Hospital do Meixoeiro
-
Kontakt:
- Beatriz Vazquez Barreiro, MD
- Numer telefonu: +34 986 81 11 11
- E-mail: Beatriz.vazquez.barreiro@sergas.es
-
-
Madrid
-
Madrid, Madrid, Hiszpania, 28034
- Rekrutacyjny
- Hospital Universitario Ramón y Cajal
-
Kontakt:
- Eva Lizarbe Fernández, MD
- Numer telefonu: +3491 336 82 22
- E-mail: eva.lizarbe@gmail.com
-
Madrid, Madrid, Hiszpania, 28034
- Jeszcze nie rekrutacja
- Hospital Ruber Internacional
-
Kontakt:
- Rafael Garcia Garcia, MD
- Numer telefonu: +34913 87 50 00
- E-mail: rafael.garciag.ce@ruberinternacional.es
-
-
Navarre
-
Pamplona, Navarre, Hiszpania, 31008
- Rekrutacyjny
- Hospital Universitario de Navarra
-
Kontakt:
- Paola Anna Jablonska, MD
- Numer telefonu: +34848 428 482
- E-mail: paolajablonska@gmail.com
-
Kontakt:
- Cristina Gutierrez, PhD
- Numer telefonu: +34848433454
- E-mail: cristina.gutierrez.povedano@navarra.es
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Age ≥18 years.
- Histologically confirmed solid tumor with one to four brain metastases.
- At least one brain metastasis considered suitable for surgical resection and stereotactic radiosurgery.
- Karnofsky Performance Status (KPS) ≥70.
- Life expectancy ≥3 months.
- Ability to undergo MRI examinations.
- Written informed consent provided.
Exclusion Criteria:
- Brain metastases from small-cell lung cancer, germ cell tumors, lymphoma, or leukemia.
- Prior radiotherapy to the index lesion.
- Leptomeningeal disease at baseline.
- Contraindication to surgery or stereotactic radiosurgery.
- Pregnancy or breastfeeding.
- Any condition that, in the investigator's opinion, would interfere with study participation or evaluation.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Inny
- Przydział: Randomizowane
- Model interwencyjny: Zadanie krzyżowe
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: preoperative radiosurgery
preoperative radiosurgery (SRS) in patients with brain metastases who are candidates for surgery |
radiosurgery (SRS) in patients with brain metastases who are candidates for surgery
Inne nazwy:
Microsurgical resection of the target brain metastasis, performed either after preoperative SRS or before postoperative SRS depending on treatment arm |
|
Inny: postoperative radiosurgery
standard treatment, consisting of surgical resection followed by irradiation of the tumor bed |
radiosurgery (SRS) in patients with brain metastases who are candidates for surgery
Inne nazwy:
Microsurgical resection of the target brain metastasis, performed either after preoperative SRS or before postoperative SRS depending on treatment arm |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Locoregional adverse event-free survival
Ramy czasowe: From randomization to the first locoregional adverse event, assessed up to 12 months after randomization
|
A side effect or complication occurring specifically in the region or site where a medical procedure or treatment-such as surgery or radiotherapy-was performed. |
From randomization to the first locoregional adverse event, assessed up to 12 months after randomization
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Meningeal Failure Rate
Ramy czasowe: 6 and 12 months after randomization.
|
Proportion of patients developing nodular meningeal disease (nMD) during follow-up, as determined by clinical assessment and brain magnetic resonance imaging (MRI). |
6 and 12 months after randomization.
|
|
Symptomatic Radiation Necrosis Rate
Ramy czasowe: 6 and 12 months after randomization.
|
Proportion of patients developing symptomatic radiation necrosis confirmed by clinical and radiological evaluation. |
6 and 12 months after randomization.
|
|
Local Control Rate
Ramy czasowe: 6 and 12 months after randomization.
|
Proportion of patients without local recurrence at the treated lesion or surgical cavity, as assessed by brain MRI. |
6 and 12 months after randomization.
|
|
Distant Brain Failure-Free Survival
Ramy czasowe: 6 and 12 months after randomization.
|
Time from randomization to the occurrence of distant intracranial failure, defined as the appearance of new brain metastases outside the treated lesion(s). |
6 and 12 months after randomization.
|
|
Overall Survival
Ramy czasowe: 6 and 12 months after randomization.
|
Time from randomization to death from any cause. |
6 and 12 months after randomization.
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Time to Whole-Brain Radiotherapy (WBRT)
Ramy czasowe: From randomization until administration of WBRT, up to 42 months.
|
Time from randomization to the administration of whole-brain radiotherapy (WBRT). |
From randomization until administration of WBRT, up to 42 months.
|
|
Health-Related Quality of Life
Ramy czasowe: Baseline, and at 3, 6, 12, 18, and 24 months after treatment.
|
Change from baseline in health-related quality of life assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Brain Neoplasm 20 (EORTC QLQ-BN20). The questionnaire includes 20 items organized into 4 disease-specific symptom scales (future uncertainty, visual disorder, motor dysfunction, communication deficit) and 7 single items. All scores are linearly transformed to a scale from 0 to 100, where a higher score represents a higher level of symptoms or worse outcome (greater symptom burden). |
Baseline, and at 3, 6, 12, 18, and 24 months after treatment.
|
|
Length of Hospital Stay
Ramy czasowe: From the date of admission for the surgical procedure until the date of hospital discharge, assessed up to 30 days.
|
Duration of hospital stay measured in days, defined as the time from the date of hospital admission for the surgical procedure until the date of hospital discharge. |
From the date of admission for the surgical procedure until the date of hospital discharge, assessed up to 30 days.
|
|
Treatment Delay
Ramy czasowe: From treatment planning to treatment completion, up to 42 months.
|
Time elapsed between the protocol-defined optimal treatment schedule and the actual administration of treatment. |
From treatment planning to treatment completion, up to 42 months.
|
Współpracownicy i badacze
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby mózgu
- Choroby ośrodkowego układu nerwowego
- Choroby Układu Nerwowego
- Procesy patologiczne
- Nowotwory według lokalizacji
- Nowotwory
- Procesy Nowotworowe
- Nowotwory Układu Nerwowego
- Nowotwory ośrodkowego układu nerwowego
- Stany patologiczne, oznaki i objawy
- Przerzuty nowotworu
- Nowotwory mózgu
- Techniki śledcze
- Lecznictwo
- Procedury chirurgiczne, operacyjny
- Radioterapia
- Techniki stereotaktyczne
- Procedury neurochirurgiczne
- Radiochirurgia
Inne numery identyfikacyjne badania
- PREOPRAD
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .